AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01649115 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Passport
Description: The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
Study NCT03654703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophophamide
Study NCT04474808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-Arginin containing foot cream
Description: The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.
Study NCT04474808 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea-containing foot cream
Description: The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
Study NCT03320265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-mAb
Description: Monthly treatment for 3 months (4 administrations)
Study NCT03320265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly treatment for 3 months (4 administrations)
Study NCT04468893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention Mental Health COVID-19
Description: The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
Study NCT04468893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Intervention Mental Health COVID-19
Description: The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
Study NCT03609814 — intervention group
Intervention type: DRUG
Intervention: Clofarabine
Description: Given IV
Study NCT03609814 — intervention group
Intervention type: DRUG
Intervention: Fludarabine Injection
Description: Given IV
Study NCT02453880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Therapy
Description: Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session.
Study NCT00603603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% inhaled oxygen via non-rebreather mask
Description: Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
Study NCT00603603 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30% inhaled oxygen via nasal cannula
Description: Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
Study NCT00452660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exjade
Study NCT04715282 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epley maneuver
Description: Epley maneuver
Study NCT01491867 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.003%
Description: Instillation of travoprost 0.003% 1/die in both eyes for 3 months
Study NCT01947101 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
Study NCT00882271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Ten Acupuncture treatments within six weeks
Study NCT00882271 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Ten Acupuncture treatments within six weeks
Study NCT02030262 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiretinal membrane peeling with fluid-air exchange
Description: The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
Study NCT02030262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epiretinal membrane peeling with fluid-SF6 exchange
Description: The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
Study NCT02239445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloral hydrate Group
Description: chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
Study NCT02239445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose dexmedetomidine group
Description: Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
Study NCT02239445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dexmedetomidine group
Description: Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
Study NCT02791529 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Skin incision performed by electrocautery
Study NCT02791529 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Skin incision performed by scalpel
Study NCT01544790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
Study NCT01544790 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
Study NCT04438356 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: M-Health
Description: The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
Study NCT03049683 — intervention group
Intervention type: OTHER
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Description: The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
Study NCT00915057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
Study NCT01456182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 1
Study NCT01456182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 2
Study NCT01456182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 3
Study NCT01456182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 4
Study NCT01456182 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 5
Study NCT02586103 — intervention group
Intervention type: DEVICE
Intervention: MRI simulation
Description: It is not a working MRI machine but sounds and feels just like the real machine.
Study NCT02010047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALK qPCR assay
Description: 72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
Study NCT01766921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study NCT04029675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
Study NCT04029675 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
Study NCT03623048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: antibacterial and anti-inflammatory mouthwash
Study NCT03623048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: anti-inflammatory cleansing mouthwash
Study NCT03623048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis extract
Description: antibacterial mouthwash
Study NCT03623048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pomegranate extract
Description: antibacterial mouthwash
Study NCT01303562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Whole grain oats and barley
Description: One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
Study NCT01303562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole grain oats and barley
Description: One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
Study NCT03873480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Administration of Marcaine without Epinephrine prior to the start of surgery
Description: The intervention is the timing of administration of marcaine without epinephrine during a trigger thumb surgery.
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m2/day, intravenous (IV), every 3 weeks
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2/day, IV, every 3 weeks
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2/day, IV, every 3 weeks
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2, oral, twice daily per 3-week cycle
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2/day, IV, every 3 weeks
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 60 mg/m2/day, IV, every 3 weeks
Study NCT00454636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 825 mg/m2, oral, twice daily for 2 weeks
Study NCT04670432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylrutoside
Description: 500 mg film-coated tablet
Study NCT03377400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: concurrent radiotherapy
Study NCT02215694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dual probiotics
Description: 2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
Study NCT02215694 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2g of powder daily without probiotics
Study NCT01376128 — intervention group
Intervention type: DRUG
Intervention: Paroxetine
Study NCT04120194 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NanoFlu
Description: Investigational quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
Study NCT04120194 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Licensed quadrivalent seasonal influenza vaccine for the 2019-20 Northern hemisphere influenza season.
Study NCT01235052 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positon Emission Tomography using 18F-FMISO
Description: We will introduce a pretherapy \[18F\]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. \[18F\]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe \[18F\]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
Study NCT03916653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: osseous resection using piezoelectric device in surgical crown lengthening
Description: In this group piezoelectric device will be used for osseous resection in crown lengthening procedure with copious irrigation of sterile saline.
Study NCT03916653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osseous resection using conventional rotary instruments in surgical crown lengthening
Description: For osseous resection in crown lengthening procedure, conventional rotary instruments will be used with copious irrigation of sterile saline.
Study NCT00113490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: motavizumab (MEDI-524)
Description: Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
Study NCT00679848 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RS2 (RESTORe Suturing System)
Description: Suturing in stomach
Study NCT02706080 — intervention group
Intervention type: OTHER
Intervention: emergency
Study NCT03903250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A-GPC
Description: Taken orally in liquid form
Study NCT03903250 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: Taken orally in liquid form
Study NCT02533583 — intervention group
Intervention type: DEVICE
Intervention: pulse oximetry (PHILIPS intelliven MP5)
Description: all newborn monitor pulse oximetry in left hand
Study NCT04137809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMBLE
Description: Treadmill walking while wearing AMBLE device; three times a week for two weeks; 45-60 minutes per session.
Study NCT04037514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Intravenous paracetamol 15 mg/kg/6h
Study NCT04037514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
Study NCT00113490 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: palivizumab 15 mg/kg
Description: Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
Study NCT02577159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
Study NCT00453570 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
Description: 0.5 mL, IM
Study NCT03557918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles.~Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria.
Study NCT00453570 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed
Description: 0.5 mL, IM
Study NCT00809042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
Study NCT00809042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-carnitine and hydroxyurea
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
Study NCT00809042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea and magnesium chloride
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
Study NCT00809042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydroxyurea,L-carnitine and magnesium chloride
Description: Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
Study NCT02260557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag
Description: Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
Study NCT02260557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching selexipag 200 μg tablets to be administered orally twice daily
Study NCT04032197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Study NCT04032197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Subcutaneous (s.c., under the skin) injections for 52 weeks. Participants will remain on their pre-study standard of care treatment (antidiabetic medication and CV medication).
Study NCT02465437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBT-101
Description: JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
Study NCT02465437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
Study NCT02465437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
Study NCT02465437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B Open-Label Extension
Description: JBT-101 20mg bid on Days 1-364